Crohn’s disease: Study on the efficacy and safety of risankizumab (FORTIFY)

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Crohn’s disease: Study on the efficacy and safety of risankizumab (FORTIFY) ClinicalTrials.gov ID: NCT03105102Sponsor: AbbVie Official title:A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance study with open-label long-term extension...

Crohn’s disease: Study on subcutaneous guselkumab (GRAVITI)

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Crohn’s disease: Study on subcutaneous guselkumab (GRAVITI) ClinicalTrials.gov ID: NCT05197049Sponsor: Janssen Research & Development, LLC Official title:Randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy...

Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD) ClinicalTrials.gov ID: NCT05242471Sponsor: Janssen Research & Development, LLC Official title:Randomized, double-blind, active- and placebo-controlled,...

Ulcerative colitis: Combination study with guselkumab and golimumab (DUET-UC)

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Ulcerative colitis: Combination study with guselkumab and golimumab (DUET-UC) ClinicalTrials.gov ID: NCT05242484Sponsor: Janssen Research & Development, LLC Official title:A Phase 2b Randomized, Double-Blind, Active and Placebo-Controlled, Multicenter,...

Ulcerative colitis: Study on the efficacy and safety of risankizumab

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Ulcerative colitis: Study on the efficacy and safety of risankizumab ClinicalTrials.gov ID: NCT03398135Sponsor: AbbVie Information provided by: AbbVie (responsible party) Official title:Multicenter, randomized, double-blind, placebo-controlled 52-week maintenance...

Ulcerative colitis: ABTECT – Maintenance therapy

by Pauline Lauterbach | Jan 26, 2026 | Active, recruitment completed, For study partners

Ulcerative colitis: ABTECT – Maintenance therapy ClinicalTrials.gov ID: NCT05535946Sponsor: Abivax S.A. Information provided by: Abivax S.A. (responsible party) Official title:A randomized, double-blind, multicenter Phase III study to evaluate the long-term efficacy...